LEXICON PHARMACEUTICALS, INC. (LXRX) Quick Ratio
- Quick ratio · latest quarter: Value 13.07×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 13.07× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $192.25M ÷ $14.71M ≈ 13.07× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 192.25M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 14.71M USD | Liabilities, Current |
| Cash and equivalents | 40.92M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 149.69M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 1.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.20M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $192.25M | $14.71M | $40.92M | $149.69M | $1.64M | $1.20M | 13.07× |
| 2026-03-31 | $182.44M | $9.90M | $38.09M | $132.57M | $11.78M | $276.00K | 18.43× |
| 2025-12-31 | $98.61M | $20.87M | $34.33M | $61.90M | $2.38M | $281.00K | 4.73× |
| 2025-09-30 | $118.28M | $21.72M | $49.66M | $66.29M | $2.33M | $158.00K | 5.45× |
| 2025-06-30 | $141.19M | $34.84M | $21.36M | $117.64M | $2.18M | $168.00K | 4.05× |
| 2025-03-31 | $242.29M | $110.69M | $62.89M | $131.95M | $47.45M | $201.00K | 2.19× |
| 2024-12-31 | $241.43M | $45.25M | $66.66M | $171.30M | $3.47M | $231.00K | 5.34× |
| 2024-09-30 | $261.26M | $36.05M | $34.55M | $223.82M | $2.90M | $636.00K | 7.25× |
| 2024-06-30 | $312.58M | $27.88M | $35.62M | $274.35M | $2.62M | $585.00K | 11.21× |
| 2024-03-31 | $357.12M | $23.40M | $96.49M | $259.10M | $1.53M | $514.00K | 15.26× |
| 2023-12-31 | $171.04M | $31.55M | $22.46M | $147.56M | $1.01M | $381.00K | 5.42× |
| 2023-09-30 | $218.75M | $32.26M | $21.12M | $197.31M | $318.00K | $336.00K | 6.78× |
| 2023-06-30 | $257.42M | $26.11M | $102.27M | $154.47M | $685.00K | $172.00K | 9.86× |
| 2023-03-31 | $106.20M | $20.37M | $26.00M | $79.94M | $261.00K | (m) | 5.21× |
| 2022-12-31 | $64.70M | $23.17M | $46.34M | $18.33M | $28.00K | (m) | 2.79× |
| 2022-09-30 | $136.24M | $18.45M | $18.83M | $117.37M | $39.00K | (m) | 7.39× |
| 2022-06-30 | $62.00M | $16.86M | $21.45M | $40.52M | $34.00K | (m) | 3.68× |
| 2022-03-31 | (m) | $18.91M | $59.52M | (m) | $37.00K | (m) | (m) |
| 2021-12-31 | $79.20M | $22.12M | $64.06M | $15.12M | $14.00K | (m) | 3.58× |
| 2021-09-30 | (m) | $34.25M | $92.12M | (m) | $23.00K | (m) | (m) |
| 2021-06-30 | (m) | $32.81M | $89.89M | (m) | $159.00K | (m) | (m) |
| 2021-03-31 | (m) | $38.99M | $97.65M | (m) | $101.00K | (m) | (m) |
| 2020-12-31 | $152.67M | $46.81M | $126.26M | $26.01M | $395.00K | $0.00 | 3.26× |
| 2020-09-30 | (m) | $78.92M | $52.25M | (m) | $1.38M | $0.00 | (m) |
| 2020-06-30 | (m) | $97.56M | $86.94M | (m) | $30.88M | $3.99M | (m) |
| 2020-03-31 | (m) | $80.32M | $55.59M | (m) | $30.14M | $4.15M | (m) |
| 2019-12-31 | (m) | $65.34M | $36.11M | (m) | $56.53M | $4.24M | (m) |
| 2019-09-30 | (m) | $44.82M | $170.20M | (m) | $56.84M | $4.48M | (m) |
| 2019-06-30 | (m) | $22.47M | $11.11M | (m) | $5.58M | $4.28M | (m) |
| 2019-03-31 | (m) | $28.22M | $45.78M | (m) | $4.39M | $4.61M | (m) |
| 2018-12-31 | (m) | $36.75M | $80.39M | (m) | $5.92M | $4.68M | (m) |
| 2018-09-30 | (m) | $68.51M | $48.90M | (m) | $2.91M | $4.75M | (m) |
| 2018-06-30 | (m) | $81.34M | $15.04M | (m) | $4.41M | $2.14M | (m) |
| 2018-03-31 | (m) | $100.37M | $20.42M | (m) | $4.48M | $2.11M | (m) |
| 2017-12-31 | (m) | $124.13M | $61.66M | (m) | $4.83M | $1.95M | (m) |
| 2017-09-30 | (m) | $128.73M | $83.29M | (m) | $10.60M | $2.15M | (m) |
| 2017-06-30 | (m) | $133.17M | $30.71M | (m) | $5.01M | $811.00K | (m) |
| 2017-03-31 | (m) | $137.06M | $2.46M | (m) | $8.73M | $236.00K | (m) |
| 2016-12-31 | (m) | $164.64M | $46.60M | (m) | $7.49M | (m) | (m) |
| 2016-09-30 | (m) | $170.11M | $38.77M | (m) | $738.00K | (m) | (m) |
| 2016-06-30 | (m) | $130.99M | $38.41M | (m) | $1.02M | (m) | (m) |
| 2016-03-31 | (m) | $121.94M | $24.68M | (m) | $741.00K | (m) | (m) |
| 2015-12-31 | (m) | $123.00M | $202.99M | (m) | $911.00K | (m) | (m) |
| 2015-09-30 | (m) | $51.80M | $61.67M | (m) | $72.00K | (m) | (m) |
| 2015-06-30 | (m) | $43.57M | $9.74M | (m) | $316.00K | (m) | (m) |
| 2015-03-31 | (m) | $45.93M | $41.96M | (m) | $170.00K | (m) | (m) |
| 2014-12-31 | (m) | $44.97M | $137.27M | (m) | $1.03M | (m) | (m) |
| 2014-09-30 | (m) | $44.27M | $26.77M | (m) | $165.00K | (m) | (m) |
| 2014-06-30 | (m) | $21.90M | $27.73M | (m) | $281.00K | (m) | (m) |
| 2014-03-31 | (m) | $17.67M | $46.52M | (m) | $471.00K | (m) | (m) |
| 2013-12-31 | (m) | $19.29M | $37.50M | (m) | $790.00K | (m) | (m) |
| 2013-09-30 | (m) | $23.60M | $19.58M | (m) | $895.00K | (m) | (m) |
| 2013-06-30 | (m) | $40.90M | $23.25M | (m) | $1.01M | (m) | (m) |
| 2013-03-31 | (m) | $17.38M | $34.25M | (m) | $863.00K | (m) | (m) |
| 2012-12-31 | (m) | $18.29M | $30.42M | (m) | $1.38M | (m) | (m) |
| 2012-09-30 | (m) | $19.05M | $20.76M | (m) | $233.00K | (m) | (m) |
| 2012-06-30 | (m) | $21.55M | $33.78M | (m) | $182.00K | (m) | (m) |
| 2012-03-31 | (m) | $20.93M | $29.01M | (m) | $186.00K | (m) | (m) |
| 2011-12-31 | (m) | $21.39M | $186.31M | (m) | $350.00K | (m) | (m) |
| 2011-09-30 | (m) | $14.81M | $30.52M | (m) | $489.00K | (m) | (m) |
| 2011-06-30 | (m) | $13.23M | $20.33M | (m) | $505.00K | (m) | (m) |
| 2011-03-31 | (m) | (m) | $20.12M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $10.78M | $47.21M | (m) | $744.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | $211.99M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $247.70M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $100.55M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $85.87M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |